NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Aprea Therapeutics Stock (NASDAQ:APRE)

Advanced

Key Stats

Today's Range
$0.39
▼
$0.49
50-Day Range
$0.41
▼
$0.79
52-Week Range
$0.39
▼
$1.49
Volume
327,164 shs
Average Volume
807,407 shs
Market Capitalization
$6.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80
Consensus Rating
Moderate Buy

Company Overview

Aprea Therapeutics is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

AI Generated. May Contain Errors.

Aprea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

APRE MarketRank™: 
3.23435843054 of 5 stars

Aprea Therapeutics scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aprea Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Aprea Therapeutics has a consensus price target of $2.80, representing about 518.0% upside from its current price of $0.45.

  • Amount of Analyst Coverage

    Aprea Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aprea Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aprea Therapeutics are expected to decrease in the coming year, from ($0.39) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aprea Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aprea Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aprea Therapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.13% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently decreased by 15.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aprea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aprea Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Aprea Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aprea Therapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.49% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    34.19% of the stock of Aprea Therapeutics is held by institutions.

  • Read more about Aprea Therapeutics' insider trading history.
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APRE Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

APRE Stock Analysis - Frequently Asked Questions

Aprea Therapeutics' stock was trading at $0.8530 at the beginning of the year. Since then, APRE stock has decreased by 46.9% and is now trading at $0.4531.

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.02.

Shares of Aprea Therapeutics reverse split on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aprea Therapeutics (APRE) raised $85 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,666,667 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

Aprea Therapeutics' top institutional shareholders include Soleus Capital Management L.P. (7.05%). Insiders that own company stock include Oren Gilad, Marc Duey and John P Hamill.
View institutional ownership trends
.

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Arcturus Therapeutics (ARCT), CrowdStrike (CRWD), Precision BioSciences (DTIL), Globus Maritime (GLBS), Intel (INTC), Micron Technology (MU) and AbbVie (ABBV).

Company Calendar

Last Earnings
11/04/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:APRE
CIK
1781983
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$1.20
Potential Upside/Downside
+518.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.60 million
Net Margins
N/A
Pretax Margin
-471,500.00%
Return on Equity
-44.69%
Return on Assets
-39.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.67
Quick Ratio
9.67

Sales & Book Value

Annual Sales
$290 thousand
Price / Sales
22.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
14,190,000
Free Float
12,702,000
Market Cap
$6.43 million
Optionable
No Data
Beta
1.74
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:APRE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners